share_log

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Benzinga Real-time News ·  Sep 15, 2022 12:04
Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment